These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1673269)

  • 1. Comparison of two newly identified tumor markers (CAR-3 and DU-PAN-2) with CA 19-9 in patients with pancreatic cancer.
    Ferrara C; Basso D; Fabris C; Malesci A; Fogar P; Meggiato T; Panozzo MP; Scalon P; Del Favero G; Plebani M
    Tumori; 1991 Feb; 77(1):56-60. PubMed ID: 1673269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum DU-PAN-2 in the differential diagnosis of pancreatic cancer: influence of jaundice and liver dysfunction.
    Fabris C; Malesci A; Basso D; Bonato C; Del Favero G; Tacconi M; Meggiato T; Fogar P; Panozzo MP; Ferrara C
    Br J Cancer; 1991 Mar; 63(3):451-3. PubMed ID: 2003987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DU-PAN-2 levels in serum and pancreatic ductal fluids of patients with benign and malignant pancreatic disease.
    Mahvi DM; Seigler HF; Meyers WC; Kalthoff H; Schmiegel WH; Metzgar RS
    Pancreas; 1988; 3(4):488-93. PubMed ID: 3174610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does serum CAR-3 play a role in pancreatic cancer diagnosis?
    Basso D; Panozzo MP; Fabris C; Meggiato T; Faggian D; Fogar P; Scalon P; Del Favero G; Plebani M; Burlina A
    Oncology; 1991; 48(1):22-5. PubMed ID: 1987495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR-3 and CA 19-9 serum levels in pancreatic cancer: any differences between two epitopes of the same mucin-like glycoprotein?
    Meggiato T; Basso D; Fabris C; Fogar P; Panozzo MP; Plebani M; Faggian D; Scalon P; Ferrara C; Del Favero G
    Dis Markers; 1990; 8(4):171-7. PubMed ID: 1708317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How does liver dysfunction influence serum CA 19-9 in pancreatic cancer?
    Basso D; Fabris C; Del Favero G; Piccoli A; Angonese C; Pasquali C; Castoro C; Plebani M; Leandro G; Burlina A
    Ital J Gastroenterol; 1990 Feb; 22(1):1-6. PubMed ID: 2131920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice.
    Ohshio G; Manabe T; Watanabe Y; Endo K; Kudo H; Suzuki T; Tobe T
    Am J Gastroenterol; 1990 Oct; 85(10):1370-6. PubMed ID: 2220731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases.
    Paganuzzi M; Onetto M; Marroni P; Barone D; Conio M; Aste H; Pugliese V
    Cancer; 1988 May; 61(10):2100-8. PubMed ID: 2834038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of cholestasis on CA 50 and CA 242 in pancreatic cancer and benign biliopancreatic diseases.
    Pålsson B; Masson P; Andrén-Sandberg A
    Scand J Gastroenterol; 1993 Nov; 28(11):981-7. PubMed ID: 8284635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical value of serum tumour markers CEA, CA 50 and CA 242 in the distinction between malignant versus benign diseases causing jaundice and cholestasis; results from a prospective study.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Anticancer Res; 1992; 12(5):1687-93. PubMed ID: 1332581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative studies on the expression of tumor-associated glycoprotein (TAG-72), CA 19-9 and DU-PAN-2 in normal, benign and malignant pancreatic tissue.
    Takasaki H; Tempero MA; Uchida E; Büchler M; Ness MJ; Burnett DA; Metzgar RS; Colcher D; Schlom J; Pour PM
    Int J Cancer; 1988 Nov; 42(5):681-6. PubMed ID: 3053465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CA 19-9 in the differential diagnosis between pancreatic cancer and chronic pancreatitis.
    Farini R; Fabris C; Bonvicini P; Piccoli A; del Favero G; Venturini R; Panucci A; Naccarato R
    Eur J Cancer Clin Oncol; 1985 Apr; 21(4):429-32. PubMed ID: 3859414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical studies on the localization of cancer associated antigens DU-PAN-2 and CA19-9 in carcinomas of the digestive tract.
    Ohshio G; Ogawa K; Kudo H; Yamabe H; Nakashima Y; Kim YC; Endo K; Watanabe Y; Manabe T; Tobe T
    J Gastroenterol Hepatol; 1990; 5(1):25-31. PubMed ID: 2103381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum CA 242: the search for a valid marker of pancreatic cancer.
    Ventrucci M; Ubalducci GM; Cipolla A; Panella MA; Ligabue A
    Clin Chem Lab Med; 1998 Mar; 36(3):179-84. PubMed ID: 9589807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlative study on expression of CA 19-9 and DU-PAN-2 in tumor tissue and in serum of pancreatic cancer patients.
    Takasaki H; Uchida E; Tempero MA; Burnett DA; Metzgar RS; Pour PM
    Cancer Res; 1988 Mar; 48(6):1435-8. PubMed ID: 3162196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ca 19-9 in the diagnosis of pancreatic carcinoma].
    Meggiato T; Basso D; Pasquali C; Angonese C; Bellinvia S; Del Favero G; Fabris C; Di Mario F; Plebani M; Pedrazzoli S
    Minerva Med; 1989 May; 80(5):431-4. PubMed ID: 2747969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer.
    Haglund C; Roberts PJ; Kuusela P; Scheinin TM; Mäkelä O; Jalanko H
    Br J Cancer; 1986 Feb; 53(2):197-202. PubMed ID: 3456787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of biliary obstruction and cholangitis on serum SPan-1 level].
    Matsumoto S; Muranaka T; Hanada K; Matsuura Y; Oshiumi Y
    Kaku Igaku; 1990 Dec; 27(12):1443-6. PubMed ID: 2290216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The patterns of coexpression of tumor-associated antigens CA 19-9, TAG-72, and DU-PAN-2 in human pancreatic cancer.
    Toshkov I; Mogaki M; Kazakoff K; Pour PM
    Int J Pancreatol; 1994 Apr; 15(2):97-103. PubMed ID: 8071575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum markers and clinical data in diagnosing pancreatic cancer: a contrastive approach.
    Fabris C; Del Favero G; Basso D; Piccoli A; Meggiato T; Angonese C; Plebani M; Leandro G; Burlina A; Naccarato R
    Am J Gastroenterol; 1988 May; 83(5):549-53. PubMed ID: 3163228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.